Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain

Bayer2,251 enrolled

Overview

Depict demographic and clinical features of patients with atrial fibrillation treated with rivaroxaban to prevent stroke and pulmonary embolism in routine clinical practice

Study Type

OBSERVATIONAL

Enrollment

2,251

Conditions

Atrial Fibrillation

Interventions

Rivaroxaban (Xarelto, BAY59-7939)DRUG

Patients treated by Physicians under approved local prescriptions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients ≥ 18 years * Patients with atrial fibrillation * Patients in treatment with rivaroxaban for stroke prevention in atrial fibrillation at least 3 months previous to inclusion period in study Exclusion Criteria: * Patients in treatment after start of study * Patients treated with other anticoagulant treatment

Locations (1)

Unnamed facility

Many Locations, Spain